li001

Triplet Therapy Shows Promise for Advanced Soft Tissue Sarcoma in Early Study

Treatment /

Interim results from the LINNOVATE study suggest that a combination of lurbinectedin (Zepzelca), ipilimumab (Yervoy), and nivolumab (Opdivo) is highly effective in advanced soft tissue sarcoma. Early data show nearly all patients achieved disease control, with untreated patients seeing some complete or partial responses. The treatment was generally manageable, though 42% of patients experienced severe […]

Triplet Therapy Shows Promise for Advanced Soft Tissue Sarcoma in Early Study Read More »

Elevar Resubmits Rivoceranib Plus Camrelizumab for FDA Review in Advanced Liver Cancer

Drug Approvals /

Elevar Therapeutics has resubmitted its FDA application for rivoceranib plus camrelizumab as a first-line treatment for unresectable liver cancer (HCC). Previous delays were due to manufacturing and inspection issues, not concerns about the drug’s safety or effectiveness. The Phase 3 CARES-310 trial showed the combination significantly outperformed the former standard, sorafenib. Patients lived a median of

Elevar Resubmits Rivoceranib Plus Camrelizumab for FDA Review in Advanced Liver Cancer Read More »

FDA Reviews Ivonescimab for EGFR-Mutated Lung Cancer After TKI Failure

Drug Approvals /

The FDA has accepted a Biologics License Application for ivonescimab (AK112), a new bispecific antibody for patients with EGFR-mutated, nonsquamous non-small cell lung cancer that has progressed after third-generation TKI treatment. Phase 3 HARMONi trial data from 438 patients showed that ivonescimab combined with chemotherapy significantly slowed disease progression. Median progression-free survival improved from 4.4

FDA Reviews Ivonescimab for EGFR-Mutated Lung Cancer After TKI Failure Read More »

Personalized First-Line Treatments Transform Care for Metastatic Pancreatic Cancer

Precision Medicine /

Treatment for metastatic pancreatic cancer is becoming more personalized, focusing on controlling aggressive disease while considering each patient’s quality of life. Doctors now tailor therapy based on a patient’s ability to tolerate side effects and their tumor’s specific biomarkers, rather than just survival statistics. The FDA-approved NALIRIFOX (2024) adds a new first-line option alongside FOLFIRINOX

Personalized First-Line Treatments Transform Care for Metastatic Pancreatic Cancer Read More »

Elevar Seeks FDA Approval for Targeted Cholangiocarcinoma Drug RLY-4008

Targeted Therapy /

Elevar Therapeutics has asked the FDA to approve lirafugratinib (RLY-4008) as a second-line treatment for cholangiocarcinoma, a rare bile duct cancer, in patients with FGFR2 gene changes. The request is based on the ReFocus trial, which included 116 patients who had already had chemotherapy but not another FGFR-targeted drug. The drug showed a 46.5% overall

Elevar Seeks FDA Approval for Targeted Cholangiocarcinoma Drug RLY-4008 Read More »

EMA Backs Targeted Akeega Therapy for BRCA-Mutated Prostate Cancer

Targeted Therapy /

European regulators have given a positive recommendation to expand the use of Akeega, a combination of niraparib and abiraterone, for patients with metastatic hormone-sensitive prostate cancer who carry BRCA1 or BRCA2 mutations. If approved, this pill—taken with prednisone and standard hormone therapy—would offer a targeted treatment option earlier in the disease, based on a patient’s

EMA Backs Targeted Akeega Therapy for BRCA-Mutated Prostate Cancer Read More »

Cervical Cancer: Highly Preventable, Yet Still a Global Health Threat

News /

Cervical cancer is highly preventable, yet it remains a major global health issue. Worldwide, it is the fourth most common cancer in women, causing over 600,000 new cases and about 350,000 deaths each year. In the United States, roughly 13,500 new cases and more than 4,000 deaths occur annually. Overall five-year survival is about 67%,

Cervical Cancer: Highly Preventable, Yet Still a Global Health Threat Read More »

Immunotherapy Breaks Tumor Defenses and Clears Metastatic Cancer

Immunotherapy /

Scientists have created a new type of immunotherapy that fights metastatic cancer by attacking the tumor’s protective cells instead of the cancer cells themselves. This approach is designed to overcome the resistance seen in many solid tumors such as lung and ovarian cancer. Solid tumors often surround themselves with tumor-associated macrophages—immune cells that are reprogrammed

Immunotherapy Breaks Tumor Defenses and Clears Metastatic Cancer Read More »

Study Reveals How Pancreatic Cancer Reprograms Tissue to Spread Early Through Nerves

Research Advances /

A new study explains how pancreatic cancer becomes aggressive and spreads very early. Researchers found that the tumor can “reprogram” its surrounding environment, allowing cancer cells to invade nearby nerves and use them as pathways to spread through the body, a process known as perineural invasion. The study shows that pancreatic tumors depend on support

Study Reveals How Pancreatic Cancer Reprograms Tissue to Spread Early Through Nerves Read More »

Immune “Memory” Marker Explains 20-Year Survival After Breast Cancer Vaccine

Research Advances /

A new study explains why a small group of women with advanced breast cancer lived more than 20 years after receiving an experimental cancer vaccine. Researchers discovered that these long-term survivors shared a special immune “memory” marker called CD27, which helps the immune system remember and fight cancer for decades. This finding is unusual because

Immune “Memory” Marker Explains 20-Year Survival After Breast Cancer Vaccine Read More »